J Neurooncol. 2025 Oct 16;176(1):20. doi: 10.1007/s11060-025-05250-3.

Autonomy duration in patients with biopsy-only unresectable IDH wild-type glioblastomas

Vincent Harlay ¹, Céline Bequet ², Romain Appay ³ ⁴, Alexandre Bertucci ² ⁴, Gregorio Petrirena ², Chantal Campello ², Maryline Barrié ², Didier Autran ², Thomas Graillon ⁵, Henry Dufour ⁵, Dominique Figarella-Branger ³ ⁴, Laetitia Padovani ⁶, Anne Barlier ⁷, Isabelle Nanni ⁸, Emeline Tabouret ² ⁴ ⁹, Olivier Chinot ² ⁴

Affiliations

PMID: 41099970 DOI: 10.1007/s11060-025-05250-3

Abstract

Purpose: "Biopsy-only" glioblastoma (BO-GB) is an understudied entity associated with a poor outcome for whom quality of life preservation is essential. Our objective was to define and determine the time of autonomy duration in BO-GB and its potential predictive factors.

Methods: Patients diagnosed with IDH wild-type BO-GB and enrolled in a prospective regional cohort from 2014 to 2017 were analyzed for their clinical features, functional status, histo-molecular profile, neuroimaging findings, and treatment details.

Results: 137 patients were included in the present analysis. Median age at inclusion was 66 years old and median KPS was 70. Median time of autonomy duration was 7.7 months (Cl95%: 5.6-9.7). In the radiotherapy - temozolomide subgroup, median time of autonomy duration was 9.1 months (Cl95%: 8.1-10.3); in the chemotherapy upfront group, median time of autonomy duration was 5.3 months (Cl95%: 3.5-7.1). Autonomy duration was correlated to patient age and overall survival but not with initial functional status. Among the 65 patients with KPS < 70 at baseline, 11 patients (16.9%) restored their autonomy under treatment. Autonomy duration was not different between these 11 patients and the patients with baseline KPS \geq 70 (p = 0.758).

Conclusion: Autonomy duration may serve as a surrogate endpoint for overall survival for BO-GB patients and may be included in future clinical trials dedicated to this frail population.

Keywords: Autonomy duration; Biopsy-only; Functional status; Glioblastoma; Unresectable.

© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

PubMed Disclaimer

1 di 1 28/10/2025, 06:31